蒙药冠心舒通胶囊预防AMI支架植入术后再狭窄疗效  

Therapeutic effect of Mongolian medicine Guanxinshutong capsule on restenosis after stenting in AMI patients

作　　者：庄红[1] 张苏川[1] 尹俊[1] 蒋伟[1] 姚峰[1] 刘波[1] 黄璐 杨萍 代天 邹勇[1] ZHUANG Hong;ZHANG Su-chuan;YIN Jun;JIANG Wei;YAO Feng;LIU Bo;HUANG Lu;YANG Ping;DAI Tian;ZOU Yong(Department of Cardiology, Affiliated Hospital of Jianghan University, Wuhan, Hubei, 430015, China)

机构地区：[1]江汉大学附属医院心血管内科,湖北武汉430015

出　　处：《心血管康复医学杂志》2019年第2期237-240,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:分析急性心肌梗死(AMI)患者支架植入术后应用蒙药冠心舒通胶囊预防再狭窄的疗效。方法:选择2014年5月-2016年5月在我院接受支架植入术治疗的108例AMI患者,被均分为常规治疗组和蒙药组(常规治疗+蒙药冠心舒通胶囊),两组疗程均1年。观察比较两组治疗3、6个月和1年后的心绞痛复发率,治疗前、1年后的血清内皮素(ET)-1、一氧化氮(NO)、C反应蛋白(CRP)水平,术后1年的冠脉再狭窄率,及心脏不良事件发生率。结果:蒙药组治疗6个月、1年的心绞痛复发率(9.25%、5.56%)显著低于治疗3个月时的(33.33%,P=0.002, 0.001),且显著低于常规治疗组(25.93%,22.22%),P=0.023, 0.012。蒙药组术后1年冠脉再狭窄率(9.26%比33.33%)显著低于常规治疗组,P=0.002。与治疗前比较,两组治疗1年后血清ET-1、CRP水平显著降低,NO水平显著升高,P均<0.01;与常规治疗组比较,蒙药组治疗1年后血清ET-1[(125.09±33.41)ng/L比(107.16±34.26)ng/L]和CRP [(18.59±4.63)mg/L比(7.23±3.74)mg/L]水平降低更显著,NO水平[(6.81±1.47)μmol/L比(11.45±1.35)μmol/L]升高更显著,P均<0.01。随访1年,蒙药组心脏不良事件发生率显著低于常规治疗组(9.26%比25.93%),P=0.023。结论:急性心肌梗死患者支架植入术后服用蒙药冠心舒通胶囊可显著预防再狭窄发生,减少心绞痛复发,降低血清ET-1、CRP水平,减少心脏不良事件发生,改善预后。Objective: To analyze therapeutic effect of Mongolian medicine Guanxinshutong (MM) capsule on restenosis after stenting in patients with acute myocardial infarction (AMI). Methods: The 108 AMI patients, who received stenting in our hospital from May 2014 to May 2016, were selected. The patients were equally divided into routine treatment group and MM group (received MM capsule based on routine treatment group), therapeutic processes of both groups was one year. Serum levels of endothelin (ET)-1, nitric oxide (NO) and C reactive protein (CRP) before and one year after treatment;recurrence rate of angina pectoris, coronary restenosis rate and incidence rate of adverse cardiac events during one-year follow-up were observed and compared between two groups. Results: Recurrence rates of angina pectoris on six months and one year after treatment were significantly lower than that of three months after treatment (9.25%, 5.56% vs. 33.33%) in MM group ( P =0.002, 0.001), and significantly lower than those of routine treatment group (25.93%, 22.22%), P =0.023, 0.012. On one year after stenting, coronary restenosis rate of MM group was significantly lower than that of routine treatment group (9.26% vs. 33.33%), P =0.002. Compared with before treatment, on one year after treatment, there were significant reductions in serum ET-1 and CRP levels, and significant rise in NO level in two groups, P <0.01 all;compared with routine treatment group on one year after treatment, there were significant reductions in serum levels of ET-1 [(125.09±33.41)ng/L vs.(107.16±34.26)ng/L] and CRP [(18.59±4.63)mg/L vs.(7.23±3.74)mg/L], and significant rise in NO level [(6.81±1.47)μmol/L vs.(11.45±1.35)μmol/L] in MM group, P <0.01 all. During one-year follow-up, incidence rate of adverse cardiac events in MM group was significantly lower than that of routine treatment group (9.26% vs. 25.93%), P =0.023. Conclusion: Mongolian medicine Guanxinshutong capsule can significantly prevent restenosis, reduce recurrence of angina pectoris, serum ET-

关 键 词：心肌梗死 支架 蒙药 

分 类 号：R542..22[医药卫生—心血管疾病]